The Washington Post has published an editorial condemning the U.S. Food and Drug Administration for declining to review Moderna's application for its mRNA flu vaccine. The editorial argues that despite positive data, the regulatory standards appear inconsistent and subject to abrupt change. The FDA has disputed allegations of bias in its decision-making. Shares of Moderna traded largely flat during Thursday's early trading session.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments